I-MAB BIOPHARMA
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .
I-MAB BIOPHARMA
Industry:
Biotechnology Pharmaceutical Product Research
Founded:
2016-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.i-mabbiopharma.com
Total Employee:
51+
Status:
Active
Contact:
+862160578000
Email Addresses:
[email protected]
Total Funding:
815 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx IPv6 Microsoft Azure DNS
Similar Organizations
InventisBio
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Visen Pharmaceuticals
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-03-23 | Tianjing Biotechnology (Shanghai) Co | Tianjing Biotechnology (Shanghai) Co acquired by I-Mab Biopharma | N/A |
Investors List
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - I-Mab Biopharma
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - I-Mab Biopharma
Alyeska Investment Group
Alyeska Investment Group investment in Post-IPO Equity - I-Mab Biopharma
Avidity Partners
Avidity Partners investment in Post-IPO Equity - I-Mab Biopharma
Lake Bleu Capital
Lake Bleu Capital investment in Post-IPO Equity - I-Mab Biopharma
OrbiMed
OrbiMed investment in Post-IPO Equity - I-Mab Biopharma
GIC
GIC investment in Post-IPO Equity - I-Mab Biopharma
Octagon Capital Partners
Octagon Capital Partners investment in Post-IPO Equity - I-Mab Biopharma
Invus
Invus investment in Post-IPO Equity - I-Mab Biopharma
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - I-Mab Biopharma
Official Site Inspections
http://www.i-mabbiopharma.com Semrush global rank: 3.35 M Semrush visits lastest month: 4.74 K
- Host name: 47.102.217.73
- IP address: 47.102.217.73
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "I-Mab Biopharma"
I-Mab Biopharma - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +862160578000 I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and …See details»
I-Mab Biopharma - LinkedIn
I-Mab Reported Third Quarter Results with the following highlights: - Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) data presented at ESMO 2024 and SITC 2024 highlights encouraging ...See details»
I-Mab Strengthens Management Team Designed to Accelerate …
Dec 20, 2021 - New appointments as part of the Company’s strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an internationally …See details»
I-Mab Biopharma Company Profile - Office Locations, Competitors …
Oct 29, 2024 I-Mab Biopharma has 3 employees across 4 locations and ¥27.64 m in annual revenue in FY 2023. See insights on I-Mab Biopharma including office locations, competitors, …See details»
I-Mab Reports 1H 2024 Financial Results, Pipeline …
Aug 28, 2024 "I am very pleased to report that we are executing on our Board's vision by establishing a new operating model as a U.S.-based global biotech company and completing the divestiture of our ...See details»
I-Mab Strengthens Management Team Designed to Accelerate …
Dec 20, 2021 Dr. Andrew Zhu, an internationally renowned oncologist, joined I-Mab as President and board director to lead the Company's global R&D organization, focusing on delivering the …See details»
I-Mab Biopharma: going global with innovative …
I-Mab Biopharma. Jielun Zhu, CFO, I-Mab Biopharma, Shanghai, China, Tel: +852 6277 4338, Website: www.i-mabbiopharma.comSee details»
I-Mab Biopharma - Overview, News & Similar companies - ZoomInfo
I-Mab Biopharma contact info: Phone number: (240) 745-6330 Website: www.i-mabbiopharma.com What does I-Mab Biopharma do? I-Mab Biopharma Co., Ltd. is a clinical …See details»
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and ...
Aug 28, 2024 I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of …See details»
I-Mab Strengthens Management Team Designed to Accelerate …
Dec 20, 2021 Dr. Andrew Zhu, an internationally renowned oncologist, joined I-Mab as President and board director to lead the Company's global R&D organization, focusing on delivering the …See details»
I-Mab | I-Mab Provides Business and Corporate Updates and …
Jun 30, 2021 E-mail: [email protected] Office line: +86 21 6057 8000. Gigi Feng, Chief Communications Officer E-mail: [email protected] Office line: +86 21 …See details»
AbbVie and I-Mab Enter Into Global Strategic Partnership for ...
Sep 4, 2020 NORTH CHICAGO, Ill., and SHANGHAI, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB) announced today that AbbVie and I-Mab have …See details»
I-Mab Provides Business and Corporate Updates and Reports …
Mar 31, 2023 I-Mab also donated US$50 thousand to BayHelix, a non-profit organization focused on global life sciences and the healthcare community, to support the relief of COVID …See details»
I-Mab | I-Mab Launches Discovery Initiative to Expand …
Mar 10, 2021 E-mail: [email protected] Office line: +86 21 6057 8000. Gigi Feng, Chief Communications Officer E-mail: [email protected] Office line: +86 21 …See details»
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and ...
Aug 28, 2024 (PRNewsfoto/I-Mab Biopharma) "I-Mab is delivering on its strategic plan, as demonstrated by our corporate development and pipeline progress in 2024, said Sean Fu, …See details»
IMAB.O - | Stock Price & Latest News | Reuters
Nov 18, 2024 Get I-Mab (IMAB.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsSee details»
I-Mab Provides Business and Corporate Updates and Reports …
Mar 29, 2022 Efforts are already underway to work towards the commercialization strategy of “preparing the organization”, “preparing the market” and “preparing the product” for …See details»
I-Mab | I-Mab Announces Encouraging Phase 1b/2 Study Results …
The study is a dose expansion portion of a Phase 1b/2 trial evaluating the safety and efficacy of the combination therapy and investigating the potential correlation between tumor CD73 …See details»
I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce …
Boston, April 8th , 2019 -- I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the development of potential first-in-class and best-in …See details»